TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 568870

Group type: EXPERIMENTAL
Intervention: DDAVP (desamino-D-arginine vasopressin, Minirin) 20 micrograms intranasally at bedtime
Number of subjects: 18
Study: 30961440

Group type: EXPERIMENTAL
Intervention: 15/40 (15% 1RM with 40% arterial occlusion pressure)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 15/80 (15% 1RM with 80% arterial occlusion pressure)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 15/0 (15% 1RM without blood flow restriction)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 70/0 (traditional high load resistance exercise)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 15/40 and 15/80 (upper body conditions)
Number of subjects: 0
Study: 28225315

Group type: EXPERIMENTAL
Intervention: Collaborative interventions including standardized insulin infusion protocols, hypoglycemia prevention bundles, audit and feedback, education, and measure‐vention
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Collaborative interventions
Number of subjects: 9
Study: 26439577

Group type: EXPERIMENTAL
Intervention: Chamomilla L., Melissa Officinalis L. and tyndallized Lactobacillus Acidophilus (H122) (Group A; n = 45)
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Lactobacillus Reuteri (DSM 17938) (Group B; n = 45)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Simethicone (Group C; n = 43)
Number of subjects: 133
Study: 24386561

Group type: EXPERIMENTAL
Intervention: Pitavastatin 2mg once daily for 4 weeks
Number of subjects: 10
Study: 21649701

Group type: EXPERIMENTAL
Intervention: Self-explanation (n = 18)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control (n = 18)
Number of subjects: 36
Study: 19659616

Group type: EXPERIMENTAL
Intervention: Catheter ablation
Number of subjects: 420
Study: 16763075

Group type: EXPERIMENTAL
Intervention: Higher perception of pros concerning smoking cessation
Number of subjects: 554

Group type: EXPERIMENTAL
Intervention: Higher self‐efficacy perception concerning smoking cessation
Number of subjects: 554

Group type: COMPARATOR
Intervention: Lower perception of pros of quitting smoking
Number of subjects: 554
Study: 15549249

Group type: EXPERIMENTAL
Intervention: Mayo-stem
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cement-free standard stem
Number of subjects: 0
Study: 11770236

Group type: EXPERIMENTAL
Intervention: High Density Diet (HDD) for 7 days followed by routine diet plus HDD for 7 days (Group A)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Routine diet plus High Density Diet (HDD) for 14 days (Group B)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Routine diet for 14 days (Group C, control group)
Number of subjects: 3
Study: 9304176

Group type: EXPERIMENTAL
Intervention: Captopril (CTP group, n = 15), 12.5 mg every 8 hours orally, from 24 hours before surgery
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (CON group, n = 15), without captopril
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Captopril (CTP group)
Number of subjects: 30
Study: 9919351

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 160

Group type: COMPARATOR
Intervention: Thiopentone
Number of subjects: 160
Study: 2654068

Group type: EXPERIMENTAL
Intervention: Flunarizine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 1253193

Group type: EXPERIMENTAL
Intervention: 400 mg practolol administered orally
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 30 mg practolol, iv
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 31338880

Group type: EXPERIMENTAL
Intervention: Antimuscarinics
Number of subjects: 507

Group type: EXPERIMENTAL
Intervention: Behavioral therapy
Number of subjects: 507

Group type: COMPARATOR
Intervention: Bladder diary
Number of subjects: 507
Study: 28549264

Group type: EXPERIMENTAL
Intervention: Family group conference (FGC)
Number of subjects: 0
Study: 25219686

Group type: EXPERIMENTAL
Intervention: Chronic care management (CCM)
Number of subjects: 563

Group type: COMPARATOR
Intervention: Usual primary care
Number of subjects: 563
Study: 22921454

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT), 12 sessions
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control subjects (healthy subjects), N=42
Number of subjects: 42
Study: 21224748

Group type: EXPERIMENTAL
Intervention: Resection of the preseptal orbicularis oculi muscle (group 1)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Preservation of the orbicularis oculi muscle (group 2)
Number of subjects: 15
Study: 19191940

Group type: EXPERIMENTAL
Intervention: Modified positioning and a pillow under their body (Group A)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Modified positioning (Group B)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Control group (routine care)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Overall bleeding and haematoma formation
Number of subjects: 105
Study: 16782644

Group type: EXPERIMENTAL
Intervention: Preoperative assessment using CT scan
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Intraoperative assessment using navigation system
Number of subjects: 24
Study: 15462115

Group type: EXPERIMENTAL
Intervention: Purified omega-3 fatty acids (PFA) at a very low dose (0.85 g EPA and 0.57 g PHA)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (symptomatic treatment)
Number of subjects: 28
Study: 11424542

Group type: EXPERIMENTAL
Intervention: Child and Adolescent Trial for Cardiovascular Health (CATCH) Food Checklist (CFC)
Number of subjects: 365
Study: 9241099

Group type: EXPERIMENTAL
Intervention: Perindopril (2‐4 mg daily)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 8320926

Group type: EXPERIMENTAL
Intervention: Acetate or bicarbonate hemodialysis using cuprophane membranes
Number of subjects: 22

Group type: COMPARATOR
Intervention: HDF or AFB using PAN membranes
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Bicarbonate-cuprophane, HDF and AFB-PAN
Number of subjects: 22
Study: 3760480

Group type: COMPARATOR
Intervention: Intravenous chemotherapy with Adriamycin, Vincaleucoblastin, Bleomycin, Fluorouracil and Ifosfamid monthly for 10 months
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Combined intravenous and intraperitoneal chemotherapy with the same drugs
Number of subjects: 20
Study: 31222977

Group type: EXPERIMENTAL
Intervention: Retinol 0.15%
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Retinol 0.3%
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (not explicitly mentioned)
Number of subjects: 40
Study: 29672468

Group type: EXPERIMENTAL
Intervention: Moulage present
Number of subjects: 50

Group type: COMPARATOR
Intervention: No moulage
Number of subjects: 50
Study: 26482056

Group type: EXPERIMENTAL
Intervention: Cholinesterase inhibitors (ChEIs) continuation
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 24473119

Group type: EXPERIMENTAL
Intervention: Contact (Visible Disability)
Number of subjects: 408

Group type: EXPERIMENTAL
Intervention: Contact (Invisible Disability)
Number of subjects: 408

Group type: COMPARATOR
Intervention: Education only
Number of subjects: 408
Study: 23197596

Group type: EXPERIMENTAL
Intervention: Primary HPV DNA screening
Number of subjects: 203425

Group type: COMPARATOR
Intervention: Conventional cytology screening
Number of subjects: 203425

Group type: EXPERIMENTAL
Intervention: HPV screening (age 25-34)
Number of subjects: 203425

Group type: COMPARATOR
Intervention: Conventional screening (age 25-34)
Number of subjects: 203425

Group type: EXPERIMENTAL
Intervention: HPV screening (age 35 and older)
Number of subjects: 203425

Group type: COMPARATOR
Intervention: Conventional screening (age 35 and older)
Number of subjects: 203425
Study: 21033135

Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 225

Group type: COMPARATOR
Intervention: Dobutamine
Number of subjects: 225
Study: 18717189

Group type: EXPERIMENTAL
Intervention: Latanoprost 0.005% stored at 4 degrees C
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Latanoprost 0.005% stored at 30 degrees C
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control (untreated eyes)
Number of subjects: 17
Study: 15892403

Group type: EXPERIMENTAL
Intervention: suxamethonium (1 mg kg(‐1))
Number of subjects: 376

Group type: EXPERIMENTAL
Intervention: rocuronium (2 x ED95)
Number of subjects: 376

Group type: COMPARATOR
Intervention: rocuronium primed with saline, atracurium, cis‐atracurium, vecuronium or mivacurium
Number of subjects: 376

Group type: EXPERIMENTAL
Intervention: mivacurium
Number of subjects: 376
Study: 12590430

Group type: EXPERIMENTAL
Intervention: Methadone therapy
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Hospital therapy without methadone
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Therapeutic community
Number of subjects: 90
Study: 10593465

Group type: EXPERIMENTAL
Intervention: Epidural analgesia (EPI) with bolus doses of morphine via an epidural catheter
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Intraarticular analgesia (IA) with 1 mg of morphine applied at the end of the operation and subsequent PCA
Number of subjects: 37

Group type: COMPARATOR
Intervention: Intravenous analgesia (Control) with PCA only
Number of subjects: 37
Study: 8697949

Group type: EXPERIMENTAL
Intervention: Air mattress
Number of subjects: 0
Study: 1662880

Group type: EXPERIMENTAL
Intervention: Temafloxacin 600 mg
Number of subjects: 492

Group type: COMPARATOR
Intervention: Ciprofloxacin 750 mg
Number of subjects: 492
Study: 7159688

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (50 mg oral dose) from Brand A
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (50 mg oral dose) from Brand B
Number of subjects: 20
Study: 30813591

Group type: EXPERIMENTAL
Intervention: Tap water supply
Number of subjects: 1369

Group type: COMPARATOR
Intervention: Alternative water sources (wells, open sources, tankered water)
Number of subjects: 1369

Group type: EXPERIMENTAL
Intervention: Water consumption
Number of subjects: 1369
Study: 27663567

Group type: EXPERIMENTAL
Intervention: Postoperative chemotherapy
Number of subjects: 162

Group type: COMPARATOR
Intervention: No chemotherapy (control)
Number of subjects: 162
Study: 27209480

Group type: EXPERIMENTAL
Intervention: Rigid gas permeable (RGP) contact lens wearers
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Keratoconus patients (KC)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 23
Study: 24611906

Group type: EXPERIMENTAL
Intervention: Fucoidan (500 mg once daily before breakfast for 3 months)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 22440498

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents (SES)
Number of subjects: 907

Group type: EXPERIMENTAL
Intervention: Abciximab
Number of subjects: 907

Group type: COMPARATOR
Intervention: Bare-metal stents (BMS)
Number of subjects: 907

Group type: COMPARATOR
Intervention: No abciximab
Number of subjects: 907
Study: 19325538

Group type: EXPERIMENTAL
Intervention: High-carbohydrate breakfast
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: High-fat breakfast
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: High-protein breakfast
Number of subjects: 26
Study: 17761591

Group type: EXPERIMENTAL
Intervention: Albumin
Number of subjects: 460

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 460

Group type: EXPERIMENTAL
Intervention: Albumin (severe brain injury subgroup)
Number of subjects: 460

Group type: COMPARATOR
Intervention: Saline (severe brain injury subgroup)
Number of subjects: 460

Group type: EXPERIMENTAL
Intervention: Albumin (GCS scores 9 to 12 subgroup)
Number of subjects: 460

Group type: COMPARATOR
Intervention: Saline (GCS scores 9 to 12 subgroup)
Number of subjects: 460
Study: 15467557

Group type: EXPERIMENTAL
Intervention: McRoberts position
Number of subjects: 27

Group type: COMPARATOR
Intervention: Lithotomy position
Number of subjects: 27
Study: 11409222

Group type: EXPERIMENTAL
Intervention: Proportional assist ventilation (PAV) with 9.8 (± 2.1) cm H2O/L and 3.3 (± 1.0) cm H2O/L/sec of volume assist and flow assist
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control trial (spontaneously breathing without assistance)
Number of subjects: 8
Study: 9715712

Group type: EXPERIMENTAL
Intervention: Duplex scanning (DD group)
Number of subjects: 179

Group type: COMPARATOR
Intervention: Clinical examination and ABI measurement (ABI group)
Number of subjects: 179
Study: 8790521

Group type: EXPERIMENTAL
Intervention: Transvaginal ultrasonography as a primary screening test and colour Doppler imaging as a secondary screening test
Number of subjects: 8678

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 8678
Study: 2532691

Group type: EXPERIMENTAL
Intervention: hANP only
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: nifedipine + hANP
Number of subjects: 20

Group type: COMPARATOR
Intervention: placebo only
Number of subjects: 20
Study: 1233250

Group type: EXPERIMENTAL
Intervention: Strophanthin K (0.125 and 0.25 MG)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Lanatoside C (0.4, 0.8 and 1.6 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 31806129

Group type: EXPERIMENTAL
Intervention: Sacubitril-valsartan
Number of subjects: 1097
Study: 28115027

Group type: EXPERIMENTAL
Intervention: Short Feedback (1-minute training with real-time visual feedback)
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Long Feedback (10-minute training with real-time visual feedback)
Number of subjects: 450

Group type: COMPARATOR
Intervention: No Feedback (NF)
Number of subjects: 450
Study: 25406300

Group type: EXPERIMENTAL
Intervention: Autologous bone marrow mononuclear cell (BMC) therapy
Number of subjects: 101
Study: 23281620

Group type: EXPERIMENTAL
Intervention: Outpatient training for 6 months
Number of subjects: 74
Study: 21242465

Group type: EXPERIMENTAL
Intervention: Contoured foot orthoses
Number of subjects: 20

Group type: COMPARATOR
Intervention: Flat foot orthoses
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Foot orthoses (both types)
Number of subjects: 20
Study: 18290996

Group type: EXPERIMENTAL
Intervention: 300 mg abacavir
Number of subjects: 600

Group type: COMPARATOR
Intervention: 200 mg nevirapine
Number of subjects: 600
Study: 16404741

Group type: EXPERIMENTAL
Intervention: DVd (pegylated liposomal doxorubicin 40 mg/m², vincristine 1.4 mg/m², dexamethasone 40 mg Days 1-4)
Number of subjects: 192

Group type: COMPARATOR
Intervention: VAd (conventional doxorubicin 9 mg/m² per day, vincristine 0.4 mg per day, dexamethasone reduced dose)
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: DVd
Number of subjects: 192
Study: 14744180

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Active treatment (neuroleptics)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both groups (Placebo and Active treatment)
Number of subjects: 100
Study: 11412157

Group type: EXPERIMENTAL
Intervention: Ropivacaine combined with sufentanil 0.75 microg.ml‐1
Number of subjects: 42

Group type: COMPARATOR
Intervention: Ropivacaine alone
Number of subjects: 42
Study: 9646213

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg twice daily for four weeks plus amoxicillin 3 g daily during the first and second week (Group A)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Omeprazole 20 mg twice daily for 4 weeks plus placebo for two weeks (Group B)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Helicobacter pylori cured patients
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Persistently Helicobacter pylori positive patients
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Helicobacter pylori-eradicated patients
Number of subjects: 59
Study: 8426317

Group type: EXPERIMENTAL
Intervention: 4.0 mm incisions
Number of subjects: 276

Group type: COMPARATOR
Intervention: 5.5 mm incisions
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 276
Study: 2885366

Group type: EXPERIMENTAL
Intervention: Clotiazepam 5 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Clotiazepam 10 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Clotiazepam 20 mg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 29709099

Group type: EXPERIMENTAL
Intervention: Spironolactone 25 mg once daily
Number of subjects: 381

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 381
Study: 28236563

Group type: EXPERIMENTAL
Intervention: Tension orthosis (Levame)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Compression orthotic device
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 30
Study: 26409407

Group type: EXPERIMENTAL
Intervention: Anodal tDCS stimulation to the primary motor cortex, 20 minutes/day for 5 consecutive days
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham tDCS stimulation
Number of subjects: 20
Study: 23991573

Group type: EXPERIMENTAL
Intervention: Music intervention
Number of subjects: 165

Group type: COMPARATOR
Intervention: Blank group (no intervention)
Number of subjects: 165
Study: 21918206

Group type: EXPERIMENTAL
Intervention: Comprehensive Diabetes Management Program (CDMP)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Attention Control (AC)
Number of subjects: 39
Study: 19065488

Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation using the HALO system
Number of subjects: 0
Study: 16687979

Group type: EXPERIMENTAL
Intervention: Tretin-X (0.1% cream, 0.025% cream, 0.025% gel, 0.01% gel)
Number of subjects: 1642

Group type: EXPERIMENTAL
Intervention: Retin-A (0.1% cream, 0.025% cream, 0.025% gel, 0.01% gel)
Number of subjects: 1642

Group type: COMPARATOR
Intervention: Placebo (drug vehicle)
Number of subjects: 1642
Study: 12654603

Group type: EXPERIMENTAL
Intervention: Simvastatin (40 mg/d)
Number of subjects: 70

Group type: COMPARATOR
Intervention: American Heart Association Step 1 diet alone
Number of subjects: 70
Study: 11543414

Group type: EXPERIMENTAL
Intervention: Resistance exercise (REX) - five sets of leg press exercise to volitional fatigue (6‐10 repetitions) every other day.
Number of subjects: 12

Group type: COMPARATOR
Intervention: No exercise (control group)
Number of subjects: 12
Study: 8867397

Group type: EXPERIMENTAL
Intervention: Early nutritional support (enteral or parenteral feeding) with appropriate caloric and protein requirement as soon as hemodynamic status was stabilized.
Number of subjects: 38

Group type: COMPARATOR
Intervention: Conventional method with administration of hypo caloric intravenous regimen and supplement with oral diet as soon as bowel function returned.
Number of subjects: 38
Study: 1363640

Group type: EXPERIMENTAL
Intervention: Cefuroxime axetil alone (500 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Cefuroxime axetil with food (500 mg)
Number of subjects: 12
Study: 6377829

Group type: EXPERIMENTAL
Intervention: Glipizide (12 micrograms/kg intravenously)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Glipizide (5 mg orally)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Glipizide (oral administration)
Number of subjects: 6
Study: 30669980

Group type: EXPERIMENTAL
Intervention: Caregivers with poor/fair self-rated health (SRH)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Caregivers with good, very good, or excellent SRH
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Caregivers with poor/fair SRH
Number of subjects: 134
Study: 28833938

Group type: EXPERIMENTAL
Intervention: OBV/PTV/r + SOF ± RBV for 12 weeks in genotype 3 infection
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: OBV/PTV/r + SOF + RBV for 8 weeks in genotype 2 infection
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: OBV/PTV/r + SOF + RBV for 6 weeks in genotype 2 infection
Number of subjects: 70
Study: 26473793

Group type: EXPERIMENTAL
Intervention: Xerostomia patients
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 30
Study: 25245446

Group type: EXPERIMENTAL
Intervention: ATRA plus arsenic trioxide
Number of subjects: 156

Group type: COMPARATOR
Intervention: ATRA plus chemotherapy
Number of subjects: 156
Study: 22357257

Group type: EXPERIMENTAL
Intervention: Primary tamoxifen (Tam)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Mastectomy with adjuvant tamoxifen (Mx + Tam)
Number of subjects: 153
Study: 20571433

Group type: EXPERIMENTAL
Intervention: venlafaxine‐XR 225 mg/d
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: mirtazapine 45 mg/d
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: paroxetine 20 mg/d
Number of subjects: 150
Study: 17174627

Group type: EXPERIMENTAL
Intervention: DDD-40
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: DDD-70
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: DDDR-40
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: Exercise substudy (minimum of 375 patients)
Number of subjects: 1200
Study: 16286163

Group type: EXPERIMENTAL
Intervention: Fasudil (up to 80 mg three times daily)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study: 12449085

Group type: COMPARATOR
Intervention: Acupuncture
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo techniques
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 0
Study: 9988133

Group type: EXPERIMENTAL
Intervention: Group I (no cortical status spongiosus)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Group II (with cortical status spongiosus)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 14
Study: 8854962

Group type: EXPERIMENTAL
Intervention: Early feeding (group I)
Number of subjects: 161

Group type: COMPARATOR
Intervention: Delayed feeding (group II)
Number of subjects: 161
Study: 2323078

Group type: EXPERIMENTAL
Intervention: Lozenge containing 11 mg L-menthol
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 499107

Group type: EXPERIMENTAL
Intervention: 2.5 ml of 20% glucose per kg body weight (Group II)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: 1.0 g chloropropamide (Group III)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control (Group I)
Number of subjects: 53
Study: 31100568

Group type: EXPERIMENTAL
Intervention: Operative rib fixation
Number of subjects: 50
Study: 28160085

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Interferential current (IFC)
Number of subjects: 40

Group type: COMPARATOR
Intervention: SHAM placebo
Number of subjects: 40
Study: 26781338

Group type: EXPERIMENTAL
Intervention: FospropofolFD 20 mg/kg
Number of subjects: 240

Group type: COMPARATOR
Intervention: Propofol 2 mg/kg
Number of subjects: 240